BioStock: Cyxone’s CEO comments on the US patent notice

Biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod. The company reached a milestone in receiving a Notice of Allowance for the US patent of Rabeximod compounds. BioStock contacted CEO Carl-Magnus Högerkorp for a comment on the prospects of the patent. 

Read the interview with Cyxone's CEO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2023/04/cyxones-ceo-comments-on-the-us-patent-notice/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/